Michael Klichinsky Sells 200,000 Shares of Carisma Therapeutics (NASDAQ:CARM) Stock

Carisma Therapeutics Inc. (NASDAQ:CARM) insider Michael Klichinsky sold 200,000 shares of the company’s stock in a transaction on Thursday, October 2nd. The stock was sold at an average price of $0.25, for a total value of $50,000.00. Following the transaction, the insider directly owned 119,347 shares in the company, valued at $29,836.75. This represents a 62.63% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Michael Klichinsky also recently made the following trade(s):

• On Friday, October 3rd, Michael Klichinsky sold 119,347 shares of Carisma Therapeutics stock. The shares were sold at an average price of $0.26, for a total value of $31,030.22.
• On Wednesday, October 1st, Michael Klichinsky sold 165,000 shares of Carisma Therapeutics stock. The stock was sold at an average price of $0.26, for a total transaction of $42,900.00.

Carisma Therapeutics Stock Down 3.4%

Shares of CARM opened at $0.26 on Friday. Carisma Therapeutics Inc. has a 52-week low of $0.14 and a 52-week high of $1.27. The company has a 50-day simple moving average of $0.30 and a 200-day simple moving average of $0.30. The company has a market capitalization of $10.90 million, a PE ratio of -0.17 and a beta of 2.06.

Wall Street Analyst Weigh In

Several brokerages have recently commented on CARM. Weiss Ratings reissued a “sell (e+)” rating on shares of Carisma Therapeutics in a research note on Saturday, September 27th. D. Boral Capital reaffirmed a “buy” rating and set a $1.00 price objective on shares of Carisma Therapeutics in a report on Friday, August 8th. Finally, Evercore ISI raised Carisma Therapeutics to a “strong-buy” rating in a report on Tuesday, July 15th. Two investment analysts have rated the stock with a Strong Buy rating, one has given a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $1.93.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Carisma Therapeutics stock. Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in shares of Carisma Therapeutics Inc. (NASDAQ:CARM) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 200,000 shares of the company’s stock, valued at approximately $62,000. Universal Beteiligungs und Servicegesellschaft mbH owned 0.48% of Carisma Therapeutics at the end of the most recent quarter. Hedge funds and other institutional investors own 44.27% of the company’s stock.

Carisma Therapeutics Company Profile

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.